Reboxetine mesylate

All mice were habituated to handling and gentle restraint for several minutes prior to ethanol access on days 1–3 of DID procedures. On day 4, the selective NRI, reboxetine mesylate (Tocris, catalog #1982), was dissolved in 0.9% saline and administered intraperitoneally 30-min prior to testing onset on the fourth day of the DID cycle. Each animal received vehicle (0.9% saline) or 10 mg/kg reboxetine (10 ml/kg body weight) in a Latin square design over 2-DID cycles. Vehicle or drug administration order was determined based on mouse drinking pattern observed on days 1 – 3 of the first DID cycle such that average baseline consumption between vehicle and drug groups were approximately equal (n=21: 11 female, 10 male). After 1-week of recovery from ethanol testing, mice underwent additional DID testing using the same Latin square design described above but with 3% sucrose in place of 20% ethanol to determine if drug effects on behavior were specific to ethanol consumption, followed by OFT as described above. Dosing based upon previous literature in C57BL6/J mice (Roni and Rahman, 2015 (link)).

Ketamine and xylazine were obtained from Midwest Veterinary Supply (Lakeville, MN). Meloxicam was obtained from Norbrook Laboratories (Overland Park, KS). Atomoxetine hydrochloride (1044469) and fluoxetine hydrochloride (F132) were obtained from Sigma-Aldrich (St. Louis, MO). Citalopram hydrobromide (1427), reboxetine mesylate (1982), N-(2-Chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP-4,2958), prazosin hydrochloride (0623), (S)-duloxetine hydrochloride (4798), propranolol hydrochloride (0624), and (R)-(−)-phenylephrine hydrochloride (2838) were obtained from Tocris Biosciences (Minneapolis, MN). Fluoxetine, citalopram, prazosin, and reboxetine were dissolved in 1% DMSO. DSP-4, phenylephrine, atomoxetine, propranolol, and duloxetine were dissolved in saline (0.9% NaCl).